| Naziv |
Akcije |
| Krečak, Ivan ; Celić-Bunikić, Sandra ; Skelin, Marko ; Lucijanić, Marko ; Verstovsek, Srdan ; Kušec, Rajko
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate // Annals of hematology, 101 (2022), 8; 1885-1886. doi: 10.1007/s00277-022-04839-2 |
|
| Krečak, Ivan ; Lucijanić, Marko ; Verstovšek, Srđan
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia // Current Hematologic Malignancy Reports, 17 (2022), 5; 155-169. doi: 10.1007/s11899-022-00670-8 |
|
| Lucijanić, Marko ; Krečak, Ivan ; Verstovšek, Srdan ; Sorić, Ena ; Galušić, Davor ; Holik, Hrvoje ; Periša, Vlatka ; Morić Perić, Martina ; Zekanović, Ivan ; Kušec, Rajko
Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis // Annals of hematology, 101 (2021), 6; 1355-1357. doi: 10.1007/s00277-021-04724-4 |
|
| Rozovski, Uri ; Verstovšek, Srđan ; Manshouri, Taghi ; Dembitz, Vilma ; Božinović, Ksenija ; Newberry, Kate ; Zhang, Ying ; Bove, Joseph E. ; Pierce, Sherry ; Kantarjian, Hagop et al.
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis // Haematologica, 102 (2016), 1; 79-84. doi: 10.3324/haematol.2016.149765 |
|
| Livun, Ana ; Newberry, Kate ; Manshouri, Taghi ; Kušec, Rajko ; Verstovšek, Srđan
Genes involved in maintaining the bone marrow stroma are dysregulated in patients with myelofibrosis: Lenalidomide treatment up-regulates SOCS3 // Anticancer Research, 35 (2015), 10; 5221-5223 |
|
| Newberry, Kate ; Manshouri Taghi ; Livun Ana ; Ying Zhang ; Kusec Rajko ; Verstovsek Srdan
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Upregulates SOCS3 // Blood. 2014. str. 1883-1883 |
|
| Randhawa, Jasleen ; Ostojić, Alen ; Vrhovac, Radovan ; Atallah, Ehab ; Verstovšek, Srđan
Splenomegaly in myelofibrosis - new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors // Journal of Hematology & Oncology, 5 (2012), 1; 43-49. doi: 10.1186/1756-8722-5-43 |
|
| Ostojić, Alen ; Vrhovac , Radovan ; Verstovšek, Srđan
Ruxolitinib for the treatment of myelofibrosis: its clinical potential // Therapeutics and clinical risk management, 8 (2012), 1; 95-103. doi: 10.2147/TCRM.S23277 |
|
| Ostojić, Alen ; Vrhovac, Radovan ; Verstovšek, Srđan
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis // Future Oncology, 7 (2011), 9; 1035-1043. doi: 10.2217/FON.11.81 |
|
| Ostojić, Alen ; Vrhovac, Radovan ; Verstovšek, Srđan
Ruxolitinib for the treatment of myelofibrosis // Drugs of today (Barcelona), 47 (2011), 11; 817-827 |
|
